Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)

Condition:   Breast Cancer Female Interventions:   Drug: Metformin Hydrochloride 850 mg Tablets;   Drug: AC-T chemotherapy regimen Sponsors:   Damanhour University;   Alexandria University Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg dai...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusions Sentinel lymph node identification using preoperative scintigraphy and intraoperative use of gamma probe seems to be a feasible and efficient method in terms of differentiating patients that require axillary lymph node dissection during breast cancer surgery, even when they have received neoadjuvant chemotherapy. Further large prospective studies allowing subgroup analyses are warranted.
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
AbstractBackgroundThe aim of the study was to develop a deep learning (DL) algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.MethodsA total of 302 breast cancer patients in this retrospective study were randomly divided into a training set (n =  244) and a validation set (n = 58). Tumor regions were manually delineated on each slice by two expert radiologists on enhanced T1 ‐weighted images. Pathological results were used as ground truth. Deep learning network contained five repetitions of convolution and max‐pooling layers and ended with three dense laye...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Neoadjuvant systemic therapy can facilitate breast conservation in certain women with stage II and III operable breast cancer. But compared to other countries, significantly fewer women in the United States make such a choice.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Conditions:   Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   Sentinel Lymph Node Intervention:   Procedure: Omission of sentinel lymph node biopsy Sponsor:   The Netherlands Cancer Institute Not yet recruiting
Source: - Category: Research Source Type: clinical trials
In this study, we enriched populations of chemoresistant cancer stem cells from breast cancer and non-transformed breast cell lines using mammospheres. These mammospheres were treated or not with two chemoreagents, and we profiled surviving cells using miRNA microarray analysis. Comparison of the profiles from treated and untreated mammospheres as well as control and cancer cells yielded a six-miRNAs signature specific for chemoresistant stem cell-enriched subpopulations. From this signature miR-363-3p was found to be most highly overexpressed in various breast cancer cell lines and derived cancer stem cell-enriched popula...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Homo sapiens Source Type: research
Conclusions: As neoadjuvant therapy, the Nab-PTX regimen has advantages over conventional taxane regimen in patients with HER2-negative breast cancer. With this regimen, a high pCR rate was achieved with a good safety profile.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
T, Nekljudova V, Untch M, Loibl S Abstract PURPOSE: In breast cancer bevacizumab increased pCR rate but not long term survival and no predictive markers are available to identify patients with long term benefit from the drug. EXPERIMENTAL DESIGN: We profiled 289 pre-therapeutic FFPE biopsies of HER2 negative patients from the GeparQuinto trial of neoadjuvant chemotherapy +/- bevacizumab by exome-capture RNA-Seq. In a prospectively planned study we tested molecular signatures for response prediction. Immunohistochemical validation was performed using tissue microarrays. RESULTS: We found strong agreement ...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher : Commentary on "Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer" by Marissa K. Srour et al. Ann Surg Oncol. 2020 Jan 13;: Authors: Groheux D, Hindié E PMID: 31933220 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
AbstractSentinel lymph node biopsy (SLNB) alone in early breast cancer is an established standard of care. However, the same results have not been replicated in locally advanced breast cancer (LABC) after neoadjuvant chemotherapy (NACT). We aim to examine the feasibility of SLNB in LABC patients post NACT to determine identification rates (IR) and false negative rates (FNR). This was a single tertiary cancer center –based prospective study from February 2017 to November 2018. Forty-four patients with LABC (T3, T4 with N0 or N1) were studied and response after NACT was assessed. Only those patients who were N0 or who ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Fortamet | Metformin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research